France's National Agency for the Safety of Medicine and Health Products (ANSM) has sanctioned pharmaceutical companies Novo Nordisk and Eli Lilly for misleading advertising.
The agency determined that the companies' campaigns, which were framed as public awareness initiatives, were actually promoting their products.
This decision, announced on May 12, 2026, highlights ongoing concerns regarding the ethical boundaries of pharmaceutical advertising.